Coverage of any medical intervention discussed in a Dean Health Plan medical policy is subject to the limitations and exclusions outlined in the member’s benefit certificate.

Quantitative and Qualitative Urine Drug Testing (UDT)  MP9460

Covered Service: Yes—when meets criteria below

Prior Authorization Required: No

Additional Information: None

Medicare Policy: Dean Health Plan covers when Medicare also covers the benefit.

BadgerCare Plus Policy: Dean Health Plan covers when BadgerCare Plus also covers the benefit.

Dean Health Plan Medical Policy:

1.0 Urine drug testing is considered medically necessary when individualized to test for substances only specific to the individual plan of treatment. Clinical documentation should specify how the test results will be used to guide clinical decision making.

1.1 If the billing provider of the service is not the prescribing, referring, or ordering provider, he or she is required to maintain documentation of the lab results along with copies of the order for the drug test.

1.2 The prescribing, ordering, or referring provider is required to state the clinical indication and medical necessity for the test in the order; this documentation and the supporting medical records must be provided by the billing provider to Dean Health Plan on request.

2.0 Frequency of testing, composition of panels, and number of analytes tested should align with clinical history, current symptoms, and other supporting evidence of continuing use and individualized to the treatment plan.

3.0 In outpatient pain management and substance abuse settings qualitative (ie. Immunoassay) urine drug testing may be considered medically necessary for:

3.1 Baseline screening before initiating treatment or at the time treatment is initiated.

3.2 Stabilization phase

3.3 During the maintenance phase documentation should support the need to continued testing.
Coverage of any medical intervention discussed in a Dean Health Plan medical policy is subject to the limitations and exclusions outlined in the member’s benefit certificate.

4.0 Quantitative (i.e. confirmatory) urine drug testing may be considered medically necessary under the follow circumstances:

4.1 When immunoassays for the relevant drug(s) are not commercially available; or

4.2 In specific situations for which quantitative drug levels are required for clinical decision making; or

4.3 Only when qualitative testing is positive.

5.0 The urine drug test ordered should be focused on detecting the specific drugs of concern, and should not routinely include a panel of all drugs of abuse.

6.0 The member should be in an active phase of treatment, chronic pain program, or actively followed by a physician in maintenance.

<table>
<thead>
<tr>
<th>Committee/Source</th>
<th>Date(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Originated: Medical Director Committee/Quality and Care Management Division</td>
<td>February 17, 2016</td>
</tr>
</tbody>
</table>

Published/Effective: 03/01/2016